← Back to Search

MCI (Amyloid Positive) for Alzheimer's Disease (GERAS-US Trial)

N/A
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights

GERAS-US Trial Summary

This study is evaluating whether a drug or a combination of drugs can slow the progression of Alzheimer's disease.

Eligible Conditions
  • Alzheimer's Disease
  • Mild Cognitive Impairment

GERAS-US Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Amyloid
Secondary outcome measures
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog14)
Bath Assessment of Subjective Quality of Life in Dementia (BASQID)
Cognitive Function Inventory (CFI)
+9 more

GERAS-US Trial Design

4Treatment groups
Experimental Treatment
Group I: Mild Dementia (Amyloid Negative)Experimental Treatment1 Intervention
Participants with mild dementia who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
Group II: Mild AD Dementia (Amyloid Positive)Experimental Treatment1 Intervention
Participants with mild AD dementia who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
Group III: MCI (Amyloid Positive)Experimental Treatment1 Intervention
Participants with mild cognitive impairment (MCI) due to AD who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
Group IV: MCI (Amyloid Negative)Experimental Treatment1 Intervention
Participants with MCI who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,613 Previous Clinical Trials
3,199,529 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,344 Previous Clinical Trials
403,852 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Journal of Alzheimer's DiseaseJournal
Observation of Patient and Caregiver Burden Associated with Early Alzheimer’s Disease in the United States: Design and Baseline Findings of the GERAS-US Cohort Study1
Robinson, Rebecca L., Dorene M. Rentz, Valerie Bruemmer, Jeffrey Scott Andrews, Anthony Zagar, Yongin Kim, Ronald L. Schwartz, Wenyu Ye, and Howard M. Fillit. 2019. “Observation of Patient and Caregiver Burden Associated with Early Alzheimer’s Disease in the United States: Design and Baseline Findings of the GERAS-US Cohort Study1”. Journal of Alzheimer's Disease. IOS Press. doi:10.3233/jad-190430.
clinicaltrials.govStudy
A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
2016. "A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02951598.
~166 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top